文献速递类风湿关节炎其他结缔组织病

风湿病患者既往HBV感染接受免疫抑制治疗时HBV再激活的前瞻性研究

Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
PubMed 文献 · Ann Rheum Dis · 2016-12-01

这项日本多中心前瞻性观察研究纳入1042例HBV表面抗原阴性且HBsAb和/或HBcAb阳性的风湿病患者,接受泼尼松龙≥5 mg/日或合成/生物免疫抑制药治疗。HBV DNA检出率为1.93/100人年,>2.1 log copies/mL为0.55/100人年,再激活者均无显性肝炎。低HBsAb滴度和高龄可能是危险因素,甲氨蝶呤风险较低而泼尼松龙较高。

要点

  • 既往HBV感染风湿病患者免疫抑制治疗中HBV再激活率1.93/100人年。
  • 再激活者包括7例使用核酸类似物者均未出现显性肝炎。
  • 低HBsAb滴度和高龄可能是再激活危险因素。

核心结论

  • 风湿病患者既往HBV感染接受免疫抑制治疗的HBV再激活率为1.93/100人年。
  • 再激活患者中未观察到显性肝炎。

研究设计与样本

  • 日本多中心前瞻性观察研究,历时2年,纳入1042例既往HBV感染的风湿病患者。
  • 入组条件为泼尼松龙≥5 mg/日和/或合成或生物免疫抑制药治疗,HBsAg阴性且HBsAb和/或HBcAb阳性。

主要发现

  • 1042例中35例检出HBV DNA,发生率1.93/100人年。
  • 10例HBV DNA>2.1 log copies/mL,发生率0.55/100人年。
  • 再激活者中7例使用核酸类似物,均无显性肝炎。
  • 低HBsAb滴度和高龄可能是HBV再激活的危险因素。
  • 3例HBsAb阳性且HBcAb阴性的患者发生再激活。

关键数值与推荐

  • 不同免疫抑制药中,甲氨蝶呤再激活风险较低,泼尼松龙较高。
  • 从开始免疫抑制治疗到再激活的间隔为3-182个月,中位66个月。

临床怎么用

  • 对既往HBV感染的风湿病患者接受免疫抑制治疗时应监测HBV DNA。
  • 低HBsAb滴度和高龄患者可能需更密切监测。
  • 使用泼尼松龙者再激活风险较高,甲氨蝶呤风险较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the reactivation of hepatitis B virus (HBV) is recognised as a serious complication in patients with rheumatic disease (RD) receiving immunosuppressive drugs (ISDs), the incidence and risk factors for reactivation remain controversial. OBJECTIVES: To investigate the incidence and risk factors for HBV reactivation in patients with RD. METHODS: We performed a multicentre, observational, prospective study over 2 years in patients with resolved HBV infection. Patients with RD treated with a dose of ≥5 mg/day prednisolone and/or synthetic or biological ISDs with negative HB virus surface antigen and positive anti-HB virus surface antibody (HBsAb) and/or anti-HB virus core antibody (HBcAb) were enrolled. Quantitative HBV DNA results and related data were regularly recorded. RESULTS: Among 1042 patients, including 959 with rheumatoid arthritis, HBV DNA was detected in 35 (1.93/100 person-years), with >2.1 log copies/mL observed in 10 patients (0.55/100 person-years). None of the reactivated patients, including seven treated with a nucleic acid analogue, showed overt hepatitis. Low HBsAb titres and advanced age seemed to be risk factors for HBV reactivation; however, reactivation was observed in three patients with positive HBsAb and negative HBcAb test results. The risk of reactivation was lower with methotrexate but higher with prednisolone among the different types of ISDs. The intervals from the start of ISD to reactivation were relatively long (3-182 months; median, 66 months). CONCLUSIONS: The incidence of HBV reactivation with ISD use was 1.93/100 person-years in patients with RD with resolved HBV infection. No overt hepatitis was observed in the reactivated patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2016. PMID: 27934678. doi:10.1136/annrheumdis-2016-209973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。